A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer
Latest Information Update: 25 Oct 2022
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Oct 2022 Status changed from recruiting to completed.
- 07 Jun 2022 Results (As of January 2022, n=371) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 14 Sep 2021 Results (as of 15 Mar 2021; n=186) presented at the 2021 World Conference on Lung Cancer.